Latest news

Bioservo Technologies AB Interim Report January – March 2022 (regulatory information)

Bioservo is investing further in Life Science

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies

Menu

17 Feb, 2022  ·  Regulatory information

Bioservo Technologies AB Year-End Report 2021

Net sales increased by 13% for the fourth quarter 2021

Fourth quarter in figures

  • Net sales of SEK 2.3 M (2.0)
  • EBITDA of SEK -7.5 M (-7.1)
  • EBIT of SEK -8.5 M (-8.1)
  • Earnings for the period amounted to SEK -8.5 M (-8.1)
  • Earnings per share before and after dilution amounted to SEK -0.45 (-0.55)
  • Cash flow from operating activities for the period amounted to SEK -8.5 M (-3.3)

Year End in figures

  • Net sales of SEK 7.1M (11.7)
  • EBITDA of SEK -30.5 M (-22.3)
  • EBIT of SEK -34.7.2 M (-26.3)
  • Earnings for the period was SEK -34.7 M (-26.3)
  • Earnings per share before and after dilution amounted to SEK -1.83 (-1.82)
  • Cash flow from operating activities for the period amounted to SEK -34.4 M (-16.6)
  • On 30 of September, cash and cash equivalents were SEK 51.5 M (52.6)

Significant events during the period

  • Bioservo Technologies AB has received certification according to ISO13485 from Lloyd´s Register Quality Assurance Limited. The certification is part of a larger investment in medical technology products for people with impaired hand function and sales in a broader international market.
     
  • To investigate how brain activity is affected by the use of a soft active exoskeleton, and thereby potentially improve rehabilitation for stroke patients, a research collaboration between Bioservo Technologies, Aleris Rehab Station Stockholm, Karolinska Institutet and the Royal Institute of Technology has been initiated.

For further information please contact:

Petter Bäckgren, CEO
petter.backgren@bioservo.com
+46 8 21 17 10

or

Madeleine Börjesson, CFO
madeleine.borjesson@bioservo.com
+46 8 21 17 10

Note: This information is such as is required by Bioservo Technologies AB under the EU Market Abuse Regulation. The information was submitted, through the care of the above person, for publication on 17 February 2022 at 08:30 (CET).


About Bioservo Technologies

Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient.

The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8-52800399, info@fnca.se is the company’s Certified Adviser on Nasdaq First North

For more information, please visit www.bioservo.com